source
- Alnylam cuts TTR franchise guidance, market cap loses $10.8B as shares tumble 28%Alnylam announced a reduction in its full-year revenue outlook for its transthyretin (TTR) franchise, trimming the midpoint by $200 million. The company now projects TTR therapy sales of $4.2 bill…
- Sanofi CEO pledges to rebuild trust and expand partnership with RegeneronSanofi's new chief executive, Belén Garijo, told analysts that restoring the relationship with longtime partner Regeneron is a top priority. She said the company wants to be more transparent and to…